Royal Pharma 2011 Limited Pharmaceutical Import Profile — Uganda (DGFT 2022–2026)

Name: Royal Pharma 2011 Limited Pharmaceutical Import Records from India — 2 Products, $8.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Royal Pharma 2011 Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $8.4M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Royal Pharma 2011 Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Innova Captab Limited	$4.1M	456	50.8%
Scott Edil Pharmacia Limited	$1.5M	67	18.6%
East African India Overseas	$1.3M	63	15.5%
Indasi Lifescience Private Limited	$320.5K	8	3.9%
Agio Pharmaceuticals Limited	$139.0K	20	1.7%
Sakar Healthcare Limited	$121.0K	7	1.5%
Zim Laboratories Limited	$100.9K	6	1.2%
S. R. Enterprises	$78.2K	8	1.0%
Sunrise International Labs Limited	$57.2K	8	0.7%
Adwik Pharma	$54.4K	2	0.7%
Uni Medicolabs	$50.0K	2	0.6%
S R Enterprises	$49.7K	3	0.6%
Globela Pharma Private Limited	$44.6K	1	0.5%
Rainbow Life Sciences Private Limited	$34.4K	2	0.4%
Ravian Life Science Private Limited	$33.7K	12	0.4%
Oscar Medicare Private Limited	$25.1K	5	0.3%
Msn Laboratories Private Limited	$24.0K	2	0.3%
Adwik Pharma Private Limited	$22.8K	3	0.3%
Alkem Laboratories Limited	$21.0K	1	0.3%
Sun Rise International Labs Limited	$20.9K	1	0.3%
Higgs Healthcare	$12.1K	5	0.1%
Bliss Gvs Pharma Limited	$7.1K	1	0.1%
Ipca Laboratories Limited	$5.0K	8	0.1%
Inventia Healthcare Limited	$4.3K	1	0.1%

Royal Pharma 2011 Limited sources from 24 verified Indian suppliers across 442 distinct formulations. The supply base is diversified across 24 suppliers, reducing single-source dependency risk.

What Formulations Does Royal Pharma 2011 Limited Import?

Formulation	Value	Ships
Roxone 1GM: (ceftriaxone injection USP	$867.7K	21
Artesunate for injection 60 MG	$510.0K	15
Rolexin-250.(cefalexin capsules BP 250MG	$208.4K	18
Artesunate for injection 60 MG with	$200.0K	4
Pharmaceuticals products formulation	$100.0K	2
Artesunate for injection 60 MG.	$99.2K	2
Pharmaceuticals products finished	$77.7K	5

What Products Does Royal Pharma 2011 Limited Import?

Top Products by Import Value

1Ceftriaxone$6.8M 2Artesunate$1.7M

Royal Pharma 2011 Limited Therapeutic Categories — 2 Specializations

Royal Pharma 2011 Limited imports across 2 therapeutic categories, with Advanced Antibiotics (79.9%), Antimalarial & Antiparasitic (20.1%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Advanced Antibiotics

1 products · 79.9% · $6.8M

Antimalarial & Antiparasitic

1 products · 20.1% · $1.7M

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ceftriaxone	Advanced Antibiotics	$6.8M	135	2.4%	1
2	Artesunate	Antimalarial & Antiparasitic	$1.7M	34	1.0%

Key Metrics

Total Import Value$8.4M

Products2

Shipments169

Categories2

CountryUganda

#1 Rankings1

Indian Suppliers24

Formulations442

Top Categories

Advanced Antibiotics79.9%

Antimalarial & Antiparasitic20.1%

Last updated: March 28, 2026

Royal Pharma 2011 Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Royal Pharma 2011 Limited is a prominent pharmaceutical importer and distributor based in Kampala, Uganda. Established on July 11, 2011, the company has expanded its operations to include multiple branches across Uganda, including locations in Lira and various districts in Kampala. The founders, Mr. Karim Nisarali Tharani and Mr. Saleem Shabuddin, have guided the company to become a key player in Uganda's pharmaceutical sector.

The company's headquarters are situated at Plot 10, Jesco Plaza, Wilson Road, P.O. Box 7429, Kampala, Uganda. Royal Pharma 2011 Limited specializes in the wholesale and retail distribution of a wide range of pharmaceutical products, including surgical instruments, medical disposables, and medical drugs that adhere to international standards. Their clientele includes over 2,500 corporate accounts and more than 5,000 other clients, such as retail pharmacies, wholesale pharmacies, drug shops, government hospitals, private hospitals, clinics, NGOs, schools, colleges, and universities.

2Distribution Network

Royal Pharma 2011 Limited operates an extensive distribution network across Uganda, with multiple branches strategically located to serve both urban and rural areas. In Kampala, the company has established several outlets, including those at Wilson Road, William Street, Nateete, and Ben Kiwanuka Street. Additionally, the company has expanded its reach to the northern region with a branch in Lira. This widespread presence enables Royal Pharma 2011 Limited to effectively distribute pharmaceutical products throughout the country.

Supplier Relationship Intelligence — Royal Pharma 2011 Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Royal Pharma 2011 Limited's sourcing strategy exhibits a high degree of concentration, particularly in its imports from India. The company has imported a total of $8.4 million USD worth of pharmaceutical products from India across 169 shipments, focusing on two primary therapeutic categories: Advanced Antibiotics and Antimalarial & Antiparasitic. The top five products imported include Ceftriaxone ($6.8 million, 2.4% share) and Artesunate ($1.7 million, 1.0% share), indicating a strategic emphasis on these medications. The reliance on a limited number of products and suppliers suggests a deliberate sourcing strategy aimed at ensuring product availability and quality. However, this concentration also introduces potential risks related to supply chain disruptions and dependency on specific suppliers.

2Supply Chain Resilience

The resilience of Royal Pharma 2011 Limited's supply chain is closely tied to its sourcing practices. With a portfolio concentration where the top five products account for 100% of imports, the company faces challenges in diversifying its product range. The heavy reliance on a select group of suppliers, particularly from India, may expose the company to risks associated with geopolitical tensions, regulatory changes, or logistical disruptions affecting these suppliers. To enhance supply chain resilience, it would be prudent for Royal Pharma 2011 Limited to explore alternative suppliers and diversify its product offerings, thereby mitigating potential risks and ensuring a more robust supply chain.

3Strategic Implications

Royal Pharma 2011 Limited's concentrated sourcing pattern positions it as a dominant player in the Ugandan market for specific pharmaceutical products, particularly Advanced Antibiotics and Antimalarial & Antiparasitic medications. This strategic focus allows the company to leverage economies of scale and establish strong relationships with key suppliers. For Indian exporters, this presents an opportunity to become alternative suppliers by offering competitive pricing, reliable delivery schedules, and adherence to quality standards. Diversifying the supplier base can also provide Royal Pharma 2011 Limited with leverage to negotiate better terms and reduce dependency on a limited number of suppliers.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Uganda — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Uganda

1Regulatory Authority & Framework

The National Drug Authority (NDA) is the primary regulatory body overseeing the pharmaceutical sector in Uganda. Established under the National Drug Policy and Authority Act (Cap 206), the NDA is responsible for regulating the manufacture, importation, exportation, sale, and supply of drugs to ensure they meet consistent high standards of quality, safety, and efficacy. The NDA's mandate includes the creation and maintenance of a national list of essential drugs, which is revised periodically to reflect the country's healthcare needs. Additionally, the NDA provides guidelines for the importation and exportation of drugs, ensuring that all pharmaceutical products entering the Ugandan market comply with established standards.

2Import Licensing & GMP

To import pharmaceutical products into Uganda, entities must obtain an import license from the National Drug Authority (NDA). This license is valid for one year and is only effective within the calendar year in which it is issued. Applicants must also hold a valid license to operate a pharmacy. Before importing each consignment, a licensed importer must apply to the NDA for a Verification Certificate, ensuring that the products meet the required standards. Regarding Good Manufacturing Practice (GMP), the NDA requires that foreign manufacturing sites pass an inspection prior to the approval of the marketing authorization application. This inspection assesses compliance with global regulatory requirements, including those of the World Health Organization (WHO). The NDA's Directorate of Inspectorate & Enforcement Services is responsible for inspecting and authorizing manufacturers of various pharmaceutical products, ensuring that medicines supplied in Uganda meet consistent high standards of quality, safety, and efficacy. (nda.or.ug)

3Quality & Labeling

Pharmaceutical products imported into Uganda must undergo batch testing to ensure they meet the required quality standards. The National Drug Authority (NDA) conducts inspections and sampling at ports of entry to verify the quality, safety, and efficacy of imported drugs. Stability requirements are also enforced to ensure that products maintain their intended quality throughout their shelf life. Labeling must comply with NDA regulations, which include requirements for labeling language, typically English, and may include other local languages. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market. These measures are part of the NDA's comprehensive approach to maintaining high standards in the pharmaceutical supply chain. (nda.or.ug)

4Recent Regulatory Changes

Between 2024 and 2026, the National Drug Authority (NDA) has implemented several policy changes affecting pharmaceutical imports into Uganda. These include stricter enforcement of import licensing requirements, enhanced inspection protocols at ports of entry, and updated guidelines for the verification of applications for importation of drugs. The NDA has also revised the national list of essential drugs to better align with the country's evolving healthcare needs. These regulatory changes aim to improve the quality, safety, and efficacy of pharmaceutical products available in Uganda, ensuring that they meet international standards. (nda.or.ug)

TransData Nexus Research · Uganda regulatory databasesMar 2026

Royal Pharma 2011 Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Royal Pharma 2011 Limited's product strategy focuses on two primary therapeutic areas: Advanced Antibiotics and Antimalarial & Antiparasitic medications. The company's imports are heavily concentrated in these categories, with the top five products accounting for 100% of its imports. This strategic focus is likely driven by the high demand for these medications in Uganda, where infectious diseases such as bacterial infections and malaria are prevalent. By concentrating on these therapeutic areas, Royal Pharma 2011 Limited aims to address critical healthcare needs and establish a strong market presence in these segments.

2Sourcing Profile

Royal Pharma 2011 Limited's sourcing strategy is heavily reliant on imports from India, with a total import value of $8.4 million USD across 169 shipments. The company imports a total of 442 unique pharmaceutical formulations, indicating a diverse product range within its focus areas. This sourcing strategy allows Royal Pharma 2011 Limited to leverage India's manufacturing capabilities and cost advantages while ensuring a steady supply of essential medications. However, the concentration of imports from a single country may expose the company to risks associated with geopolitical tensions, regulatory changes, or logistical disruptions affecting Indian suppliers.

3Market Positioning

Based on its product mix, Royal Pharma 2011 Limited primarily serves the wholesale distribution segment of the Ugandan pharmaceutical market. The company's focus on Advanced Antibiotics and Antimalarial & Antiparasitic medications positions it to meet the needs of government hospitals, private clinics, NGOs, and educational institutions. By concentrating on these therapeutic areas, Royal Pharma 2011 Limited addresses critical healthcare needs and establishes a strong market presence in these segments. The company's extensive distribution network further enhances its ability to serve a wide range of clients across Uganda.

TransData Nexus Research · DGFT trade data analysisMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Royal Pharma 2011 Limited identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Royal Pharma 2011 Limited's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 169 individual customs records matching Royal Pharma 2011 Limited.
5.Supplier Verification: Royal Pharma 2011 Limited sources from 24 verified Indian suppliers across 442 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

2 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Royal Pharma 2011 Limited

Royal Pharma 2011 Limited — Import Portfolio & Supplier Network